Novo Nordisk Trade: 45.9% Gain Fully Explained (in 16 Days)
By Stephen Manning · · 3 min read
Discover how a Novo Nordisk long call gained 45.9% in 16 days and what this means for traders.
Hello, fellow traders! I'm Stephen from Cashflow University. Today, I want to walk you through an insightful trade analysis of a recent success we had with Novo Nordisk, which resulted in a 45.9% gain in 16 days. Let's dive into the trade details and understand the reasons behind our decision.
Watch the Full Trade Breakdown
Understanding Novo Nordisk
📊 Company Snapshot
Before we delve into the trade analysis, it's important to get a glimpse of Novo Nordisk, a Danish pharmaceutical giant. Novo Nordisk's market value has at times exceeded Denmark's entire GDP. Their portfolio includes well-known products like Ozempic and Rybelsus. The latter, a daily oral tablet retailing between $150 to $300 monthly, is significantly cheaper than their injectable options, making it an attractive new addition to their lineup.
The Trade Alert: Christmas Eve Setup
Our success story began on Christmas Eve, December 24th. One of our top traders, Kyle, who is very active and insightful in our Discord community, issued a trade alert for a long call strategy on Novo Nordisk.
While Kyle predicted a mid-year bullish trend, the opportunity bloomed faster than anticipated thanks to an FDA approval catalyst.
Kyle's Technical Analysis
💡 Kyle's Key Insights
Kyle's technical analysis was crucial to this trade's success. He highlighted two key support lines on his chart — a diagonal trend line and a horizontal support floor. These indicators suggested a strong entry point at a time when the stock was near major support.
The technical setup was compelling:
- Diagonal trend line support — providing dynamic support as the stock consolidated
- Horizontal support floor — a key level where buyers had consistently stepped in
- Catalyst-driven approach — FDA approval expected to boost stock value
- Competitive positioning — Novo Nordisk competing directly with Eli Lilly's Zep Bound
Kyle's insight linked this setup to Novo's upcoming FDA approvals, which we expected to boost stock value — a prediction that indeed came true.
Trade Execution and Profit Booking
Novo Nordisk received FDA approval, pushing its stock price up to the $60 area. This surge allowed us to exit on January 9th, 2026 at $15.90 a share, securing our 45.9% gain, or $500 per contract.
As the stock hit resistance levels near the 200-day moving average, it was an ideal time to book profits. This demonstrates the importance of having clear exit criteria — we didn't get greedy, we took our profits at a logical technical resistance level.
Kyle's Track Record
At Cashflow University, we keep track of our trades through various platforms. By accessing the CFU website at joincfu.com, members can log in to view open positions, detailed analyses, and trade track records.
Kyle's public record shows 107 winners in 119 closed trades through 12 January 2026. His consistent approach to combining technical analysis with fundamental catalysts is a key part of his success.
Key Takeaways
🎯 Key Takeaways
- Catalyst-driven trades — FDA approvals can create significant short-term momentum
- Technical confluence — Multiple support levels increase trade probability
- Clear exit strategy — Taking profits at resistance (200-day MA) prevents giving back gains
- Community insights — Active Discord members like Kyle share real-time trade ideas
- Track record matters — Following traders with proven win rates improves your odds